“82% of physicians surveyed strongly agree the peripheral artery lesions they are treating today are more complex …*”

*Cagent Vascular Market Research Survey, 2016

Introducing Serration Technology

“A new approach to vessel dilatation is long overdue for treatment of diseased peripheral arteries. Today, we are treating more complex lesions that require better tools. We believe Serration Technology will prove to be effective in treating these complex lesions and will evolve into the new standard of care for vessel dilatation.”

Peter Schneider, MD

Serration Technology
Multiple Serrated Scoring Elements
Angioplasty
Mechanical Balloon Dilatation
Serranator®
The Serranator® is designed to create linear, interrupted scoring along the endoluminal surface to aid in arterial expansion

PERIPHERAL ARTERY DISEASE (PAD) IS A VERY SERIOUS MEDICAL CONDITION

Classical Masterpiece

The Serranator: “to Serrate and Serenade

Cagent Vascular has developed the Serranator Alto, an angioplasty balloon for the treatment of peripheral artery disease. The Serranator is an angioplasty balloon that incorporates serration technology – the first of its kind. It is composed of four embedded serrated metal strips on a nylon, semi-compliant balloon.

LEARN MORE

Product Specifications:

  • 6F Sheath with 0.018” Guidewire
  • 4.0, 5.0, 6.0 mm Balloon Diameters
  • 40, 80, 120 mm Balloon Lengths
Device_Master1A
Mechanism of Action: Video
Click to see Video
ClinicalDataChart-03

Clinical Data

Preliminary study data indicates that the Serranator® Alto is safe and effective in treating femoro-popliteal disease.  There was 100% device technical success. The acute results of this feasibility study demonstrate that the Serranator® Alto can safely achieve low residual stenosis.  Successful lumen gain was achieved with an average post diameter stenosis of 23%, from a pre-procedure of 88%.  In a majority of subjects (68%), the lumen gain was achieved with only 6 ATM of pressure.  Serrations were documented by OCT or IVUS in all subjects (n=10) who underwent post Serranator imaging.  The final study results including 6 month follow up are expected by the close of 2017.

NEWS

June 5th, 2017

Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, including the FDA 510(k) cleared Serranator® Alto PTA Serration Balloon Catheter, announces the completion of enrollment in the First-in Human PRELUDE Study.

Read full press release here

Meet the Conductors

Carol Burns_phoyo

President & CEO Co-Founder

 

Carol Burns

Carol Burns is a serial entrepreneur with extensive experience working in the cardiovascular sector. She has proven success in raising capital, recruiting high performance management teams and top scientific advisors.Ms. Burns has led product development, created worldwide product awareness and has achieved regulatory milestones in a high-quality, timely and capital efficient manner.

Robert Giasolli

Chief Technology  Officer, Co-Founder

 

Robert Giasolli

Robert Giasolli is a co-founder of Cagent Vascular serving as the Vice President of Research and Development and is the lead inventor of the Serranator Serration Balloon Catheter. Previously, Mr. Giasolli was a co-founder, inventor and VP of Research and Development of Intact Vascular. Robert was the chief designer for the Tack Endovascular System™.

peter johansson BW

Chief Operations Officer

 

Peter Johansson, PE

Peter Johansson has over 25 years of experience in the medical device industry with particular expertise in cardiovascular products. Peter also has extensive knowledge of and development experience with customized Quality Management Systems for medical devices.

Schneider Peter_phoyo 2

Chief Medical Officer, Co-Founder

 

Peter Schneider, MD

Dr. Schneider is a Board Certified Vascular Surgeon who currently practices at Kaiser Permanente Clinic in Honolulu, Hawaii. He is a graduate of Johns Hopkins University School of Medicine. Dr. Schneider is an early adopter of endovascular techniques and has authored many multiple scientific publications and books.

Meet the Orchestra

Medical Advisory Board

Marianne Brodmann, MD
Professor of Internal Medicine Division of Angiology
Medical University Graz
Graz, Austria

Jeffrey P. Carpenter, MD
Cooper University Physicians
Vascular and Endovascular Surgery
Cooper Medical School of Rowan University
Vice President Surgical Services & Chief of Surgery
Cooper University Healthcare
Camden, NJ

Andrey Espinoza, MD, FACC, FSCAI
Founder Advanced Heart and Vascular Institute of Hunterdon
Flemington, NJ

Mark J. Garcia, MD, MS, FSIR
Vascular and Interventional Radiology
EndoVascular Consultants, LLC
Wilmington, DE

William A. Gray, MD
System Chief, Division of Cardiovascular Diseases
Main Line Health
President, Lankenau Heart Institute
Philadelphia, PA

Llewellyn Lee, MD
Interventional Radiology
Chief, Department of Radiology
Fort Belvoir Community Hospital
Fort Belvoir, VA

Jihad A. Mustapha, MD, FACC, FSCAI
Director of Cardiovascular Research
Metro Health Hospital, Wyoming, MI
Associate Clinical Professor of Medicine
Michigan State University College of Osteopathic Medicine
E. Lansing, MI

Mahmood Razavi, MD
Mahmood K. Razavi, MD, FSIR, FSVM
Medical Director,
Comprehensive Aortic Center
Director, Dept. of Clinical Trials
St. Joseph Heart & Vascular Center
Orange, CA

Peter A. Schneider, MD
Co-founder, Chief Medical Officer, Cagent Vascular
Chief of Vascular Surgery
Kaiser Permanente Moanalua Medical Center
Honolulu, HI

Gregg W. Stone MD
Professor of Medicine
Columbia University
Director of Cardiovascular Research and Education
Center for Interventional Vascular Therapy
New York Presbyterian Hospital/ Columbia University Medical Center
Co-Director of Medical Research and Education
The Cardiovascular Research Foundation
New York, NY

Contact Us

150 Strafford Avenue #315
Wayne, PA 19087
610-688-2006
info@cagentvascular.com

The Serranator® is a trademark of Cagent Vascular, LLC